FDA pushes PDUFA for Nektar opioid analgesic

FDA pushes PDUFA for Nektar opioid analgesic

Submitted by admin on February 28, 2019 - 9:16pm
Source: 
BioCentury
News Tags: 
Nektar
FDA
NKTR-181
opioids
chronic low back pain
Headline: 
FDA pushes PDUFA for Nektar opioid analgesic
snippet: 

Nektar Therapeutics Inc. (NASDAQ:NKTR) said late Thursday that FDA has extended by three months its review of an NDA for NKTR-181 to treat chronic low back pain in adults new to opioid therapy. NKTR-181's new PDUFA data is Aug. 29.

Do Not Allow Advertisers to Use My Personal information